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Background: Suberoylanilide hydroxamic acid (SAHA) is a member of the hydroxamic acid class of the newly
developed histone deacetylase inhibitors. Recently, Suberoylanilide hydroxamic acid has attracted increasing
attention because of its antitumor activity and synergistic effects in combination with a variety of traditional
chemotherapeutic drugs. Paclitaxel (PTX), is a natural anticancer drugs; however, resistance to paclitaxel has become
a major challenge to the efficacy of this agent. The purpose of this study was to investigate the effects of the
combined application of these two drugs on the paclitaxel-resistant ovarian cancer OC3/P cell line.
Methods: In the present study, the effects of Suberoylanilide hydroxamic acid or/and paclitaxel on OC3/P cells
cultured in vitro were analyzed in terms of cell viability, migration, cell-cycle progression and apoptosis by CCK-8,
wound healing and flow cytometry assays. Changes in cell ultrastructure were observed by transmission electron
microscopy. The expression of genes and proteins related to proliferation, apoptosis and drug resistance were
analyzed by quantitative real-time polymerase chain reaction and Western blot analyses.
Results: There was no cross-resistance of the paclitaxel-resistant ovarian cancer OC3/P cells to Suberoylanilide
hydroxamic acid. Suberoylanilide hydroxamic acid combined with paclitaxel significantly inhibited cell growth and
reduced the migration of OC3/P cells compared with the effects of Suberoylanilide hydroxamic acid or paclitaxel
alone. Q-PCR showed the combination of Suberoylanilide hydroxamic acid and paclitaxel reduced intracellular
bcl-2 and c-myc gene expression and increased bax gene expression more distinctly than the application of SAHA
or paclitaxel alone. Moreover, the level of mdr1 gene expression in cells treated with Suberoylanilide hydroxamic
acid was lower than that of the control group (P <0.05). Western blot analysis showed that Suberoylanilide hydroxamic
acid alone or in combination with paclitaxel enhanced caspase-3 protein expression and degraded ID1 protein
expression in OC3/P cells.
Conclusion: Suberoylanilide hydroxamic acid inhibited the growth of paclitaxel-resistant ovarian cancer OC3/P
cells and reduced migration by the induction of cell-cycle arrest, apoptosis and autophagy. These observations indicate
the possible synergistic antitumor effects of sequential Suberoylanilide hydroxamic acid and paclitaxel treatment.
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Epithelial ovarian cancer is the most lethal gynecologic
malignancy [1]. Because of onset concealment, most
patients are diagnosed in the middle or late stages of the
disease, which makes combination chemotherapy the
major strategy for ovarian cancer treatment. Although
traditional combination chemotherapy, such as paclitaxel
(also known as Taxol) combined with cisplatin, has im-
proved the prognosis of the initial treatment of ovarian
cancer, the 5-year survival rate of advanced-stage ovarian
cancer is still between 15% and 20%, due to extensive
primary and secondary drug resistance [2-6]. Therefore,
the identification of new sensitive drugs and chemother-
apy optimization programs for ovarian cancer in cases of
chemotherapy resistance is imperative.
Although the molecular mechanisms underlying the oc-
currence and development of ovarian cancer are poorly
understood, it has been confirmed that the occurrence of
this type of cancer is closely associated with gene muta-
tion, oncogene amplification and tumor suppressor gene
deficiency [7]. With the development of epigenetics re-
search, DNA methylation and histone acetylation have
been shown to play important roles in tumor development
[8], and they have become potential targets for chemo-
therapeutic intervention. HDAC inhibitors (HDACIs),
which have attracted increasing attention in cancer
drug development, exert anticancer activities by inhi-
biting cell proliferation and inducing cell-cycle arrest
and apoptosis [9-11]. Suberoylanilide hydroxamic acid
(SAHA) is a HDACI that shows strong anti-proliferative
effects on various cancer cell lines and is currently in
clinical trials for the treatment of certain solid and
hematological tumors [12-15]. Moreover, SAHA is cur-
rently FDA-approved only for the treatment of pro-
gressive or recurrent cutaneous T-cell lymphoma
(CTCL) for which the systematic treatments have
failed [16]. In addition, SAHA shows sensitizing and
synergistic effects with a variety of traditional che-
motherapic drugs [17-19]. In particular, SAHA has
been shown to inhibit the survival of sensitive ovarian
cancer, and to have synergistic effects in combination
with decitabine and paclitaxel [18-23]. There are cur-
rently no reports of systematic studies on the mechan-
ism of the effects mediated by SAHA, alone and in
combination with PTX, on paclitaxel-resistant ovarian
cancer cell lines.
The specific goal of this study was to evaluate the anti-
cancer effects of PTX or SAHA alone or in combination
on OC3/P cells by investigating on cell viability, cell mi-
gration and invasion, cell ultrastructure, cell-cycle and
apoptosis. Changes in the expression of genes and pro-
teins related to apoptosis and drug resistance were also
evaluated. Our study showed that SAHA inhibited the
growth of OC3/P cells and reduced migration by theinduction of cell-cycle arrest, apoptosis and autophagy.
These observations indicate the possible synergistic anti-
tumor effects of sequential SAHA and PTX treatment;
however, further investigation of the functional mechan-
ism should be carried out.
Results
Differences in biological properties between OC3 and
OC3/P
As shown in Figure 1A, the aberrant nuclei were more
prevalent among OC3/P cells than OC3 cells. The ap-
pearance of the OC3/P cells was mainly fusiform com-
pared to the rounded shape of the OC3 cells. Growth
curves for the two cell lines are shown in Figure 1B. The
growth doubling-time of the OC3 cell line was approxi-
mately 27 h compared with 38 h for the OC3/P cell line.
Moreover, mdr1 expression in OC3/P was approximately
100 times greater than that in OC3 (Figure 1C). The
IC50 values of the OC3 and OC3/P cell lines and the RI
of OC3/P are shown in Table 1.
Viability of OC3 and OC3/P treated with SAHA or PTX
The viabilities of the paclitaxel-sensitive and paclitaxel-
resistant ovarian cancer cells (OC3 and OC3/P, respect-
ively) treated with SAHA or PTX were compared. Both
drugs exerted a concentration-dependent cytotoxic effect
on both cell lines (Figure 2). The PTX-mediated growth
inhibition of the sensitive cell line (OC3) was signifi-
cantly greater than that of the resistant cell line (OC3/P)
over the concentration range from 0.2 μM to 200 μM
(Figure 2A; P <0.05). There was no significant difference
in the viabilities of the two cell lines during a 48-h cul-
ture in the presence of 4, 16, 64 μM SAHA (Figure 2B;
P >0.05).
Effects of SAHA combined with PTX on cell growth and
migration capability
In every set of experiments, combined treatment with
SAHA and PTX resulted in a significantly more pro-
nounced reduction in cell viability compared with SAHA
or PTX treatment alone (Figure 3).The viability of OC3/
P treated with 2 μM PTX for 24 h was (91.70 ± 6.17)%,
which was not significantly different from that of the
control group (P >0.05). The viability of OC3/P treated
with SAHA at 4, 16 and 64 μM for 24 h was (84.31 ±
0.81)%, (71.18 ± 2.83)% and (66.42 ± 1.89)%, respectively.
However, the viability of cells pretreated with SAHA at
these concentrations for 24 h followed by culture with
2 μM PTX medium for a further 24 h was (54.75 ±
7.54)%, (40.86 ± 7.77)% and (23.73 ± 4.43)%, respectively.
These results also indicated the potential of SAHA for
the reversal of drug resistance.
The effects of SAHA or/and PTX on cell migration
and invasion were determined with scratch wound healing
Figure 1 Biological properties of the OC3 and OC3/P cell lines. A: morphology of two cell lines viewed by inverted light microscopy (original
magnification, ×20 and × 40). B: OC3 and OC3/P cell growth curves. Cell viability was determined with the CCK-8 assay every 24 h, for 6 days.
C: Basal levels of mdr1 mRNA analyzed by Q-PCR. Relative expression was calculated following normalization to GAPDH levels.
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no migration of OC3/P cells occurred within 36 h, while
varying degrees of cell migration occurred in the groups
treated with SAHA or PTX alone (Figure 4). These results
suggested that SAHA combined with PTX reduced cell
migration and invasion capacity than SAHA or PTX treat-
ment alone.
Effects of SAHA combined with PTX on autophagy and
cell-cycle
Figure 5B indicates that treatment with SAHA induced
the formation of autophagosomes in a concentration-




24 h 48 h
OC3 2.74 ± 0.29 0.29 ± 0.24 1
OC3/P 28.43 ± 3.70 3.02 ± 1.67 10.15 ± 0.33
(n = 3) (x ±S).
IC50: half maximal inhibitory concentration, RI: resistance index.24 h did not induce OC3/P cell autophagy. Combination
treatment with SAHA and PTX further enhanced the
number of autophagosomes compared with SAHA treat-
ment alone (Figure 5A).
In this study, cell-cycle progression in OC3/P cells treated
with SAHA (16 μM) or/and PTX (2 μM) was examined by
flow cytometry. Both SAHA and PTX induced OC3/P ar-
rest in the G2/M phase. SAHA combined with PTX
increased the cell accumulation in the G2/M phase to (48.7
±4.49)%, SAHA or PTX increased the G2/M phase to
(40.9 ± 12.66)% and (34.5 ± 10.32)%, respectively, compared
with that in the control group (11.9 ± 2.63)%. SAHA com-
bined with PTX increased the cell accumulation in the S
phase to (22.02 ± 6.28)%, SAHA or PTX increased the S
phase to (25.29 ± 1.17)% and (49.67 ± 5.25)%, respectively,
compared with that in the control group (15.42 ± 3.18)%.
Effects of SAHA combined with PTX on apoptosis
In this experiment, cell autophagy and changes in apop-
tosis were observed by electron microscopy. As shown
in Figure 5, the integrity of the cell membrane was intact
Figure 2 Viability of OC3 and OC3/P cell lines treated with PTX or SAHA. A: Viability of OC3 and OC3/P treated with various concentrations
of PTX for 24 h. **P <0.01, *P <0.05. B: Viability of OC3 and OC3/P treated with various concentrations of SAHA for 48 h. No significant differences
were observed between OC3 and OC3/P cell viability at any of the dose (P >0.05), implying that OC3/P is not cross-resistant to SAHA. Data represents
the mean of three independent experiments. Error bars indicate one standard deviation from the mean.
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round nuclei, evenly distributed chromatin and cyto-
plasm stretched in a star-shape into the interconnecting
space or fused with neighboring cells in the control
group. Cells treated with PTX (2 μM) for 24 h did not
show any changes typical of apoptosis, but increased cell
abnormalities were observed. The number of microvilli
on the cell surface decreased or disappeared and was ac-
companied by cell shrinkage, cytoplasm and chromatin
condensation, marginalization (crescent-shaped or
capped nuclear envelope) following treatment with
SAHA (16 μM) alone or in combination with PTX. The
typical changes of apoptosis were more significant in the
combination group than in the SAHA alone group.Figure 3 Viability of OC3/P cells treated with SAHA or/and PTX. Value
one standard deviation from the mean. The experimental method was den
(the combination of SAHA and PTX compared with treatment with each inFurthermore, the apoptotic changes in each group de-
tected by the Annexin V-FITC/PI assay were consistent
with the changes in apoptosis observed by electron mi-
croscopy. As shown in Figure 6, no significant apoptosis
was observed in OC3/P cells treated with PTX (2 μM) for
24 h. However, significantly higher rates of apoptosis were
induced in OC3/P cells by SAHA combined with PTX
than by SAHA or PTX alone (P <0.01).
Effects of SAHA combined with PTX on the genes and
proteins in OC3/P
As indicated in Figure 7A, a significant decrease in bcl-2
expression and a parallel increase in bax expression was
observed following SAHA + PTX treatment compareds represent the mean of three separate experiments. Error bars indicate
oted in Cell viability of methods. **indicates a significant difference
dividual agent) where P <0.01.
Figure 4 Wound healing assays to assess the migration and invasion capacity of OC3/P cells treated with SAHA and/or PTX. OC3/P cells
in the exponential growth phase were trypsinized and plated into 6-well plates (4 × 104cells/well). After incubation at 37°C under 5% CO2 for
24 h, cells were treated with PTX or SAHA alone or in combination (The pretreatment time and the details of co treatment was same with way in
Cell viability of methods). A wound was made by scraping the cell monolayers with a 200 μl micropipette tip. Photographs were taken immediately
and after 12 h, 24 h and 36 h using an IX70 microscope (OLYMPUS, Japan). (Scale bar, 500 μm).
Liu et al. Cancer Cell International 2014, 14:112 Page 5 of 11
http://www.cancerci.com/content/14/1/112with control group, SAHA or PTX alone (P <0.05). As
shown in Figure 7B, a downregulation in c-myc expression
in OC3/P cells was observed following treatment with
16 μM SAHA for 24 h. This effect was exacerbated by
treatment with 16 μM SAHA combined with 20 μM PTX
(P <0.05). Moreover, an increase in mdr1 expression was
observed in cells treated with 2 μM PTX for 24 h, with a
parallel decrease in mdr1 expression observed followingFigure 5 Autophagy and cell-cycle regulation of OC3/P cells treated w
24 h and then cultured with 2 μM PTX for a further 24 h, or were treated w
Cell morphology and structure were viewed by transmission electron micro
followed by serum-free 1640 for 24 h. Cell morphology and structure were
autophagosomes. N, nucleus; M, mitochondria. C: OC3/P cells were treated
(methods as above). The fractions of cells in G1-phase, S-phase and G2/M ptreatment with SAHA alone or in combination with PTX
(Figure 7C).
In addition, Western blot analysis revealed that com-
bined treatment with SAHA and PTX increased the ex-
pression of cleaved caspase-3 compared with that observed
following SAHA or PTX treatment alone. Treatment with
SAHA or PTX alone or in combination reduced the ex-
pression of ID1 protein (Figure 7D).ith SAHA or/and PTX. A: Cells were pretreated with 16 μM SAHA for
ith serum-free 1640 for 24 h followed by PTX 1640 dilution for 24 h.
scopy. B: Cells were treated with 4, 16 and 64 μM SAHA for 24 h
viewed by transmission electron microscopy. The arrows indicate
with SAHA, or PTX, or a combination of both as described previously
hase were determined by flow cytometry.
Figure 6 Annexin V-FITC/PI staining and flow cytometric analysis of apoptosis in OC3/P cells treated with SAHA or/and PTX. A: A1:
Control, A2: 2 μM PTX, A3: 20 μM PTX, A4: 16 μM SAHA, A5: 16 μM SAHA + 2 μM PTX, A6: 16 μM SAHA + 20 μM PTX(methods as above);
B: Percentages of apoptotic cells are displayed as the mean ± SD of three independent experiments performed in triplicate. *P <0.05 and **P <0.01,
indicate significant differences compared with SAHA and PTX single-agent treatments.
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In this study, we first compared differences in OC3 and
its paclitaxel-resistant cell line, OC3/P, in terms of
morphology and doubling-time. The results showed that
paclitaxel-resistant ovarian cancer cells have high atypia,
a long doubling-time compared with the characteristics
of the paclitaxel-sensitive cells. These observations are
consistent with the known difficulties in the treatment
of paclitaxel-resistant ovarian cancer and the poor prog-
nosis in such patients. The occurrence of drug resistance
in malignant tumors tends to cross-resistance to a var-
iety of chemotherapic drugs, thereby reducing their
curative effects. Previous reports have shown that OC3/
P exhibits obvious cross-resistance to Topotecan [24].
The RI of OC3/P cells used in this experiment was
10.15, with mdr1 gene expression nearly 100 times
greater than that in OC3 cells (Figure 1). Further studies
showed that SAHA exerted an obviously adverse effect
on the growth of OC3 cells and the drug-resistant OC3/
P cells; however, there was no statistical difference in
this effect between the two cell lines (Figure 2). These
results suggested that OC3/P is not cross-resistant to
SAHA, indicating the potential for its use in OC3/P
treatment.
OC3/P cells were pretreated with different concentra-
tions of SAHA for 24 h followed by treatment with
2 μM PTX for 24 h. Compared with PTX or SAHA
alone, PTX combined with SAHA significantly enhanced
the inhibition of cell growth and decreased the cell mi-
gration capability (Figures 3 and 4), indicating thatSAHA increased the sensitivity of OC3/P to PTX. Our
data indicated that pretreatment with SAHA for 24 h re-
sulted in cell-cycle arrest in the G2/M phase (Figure 5C)
and enhanced the antitumor effects of PTX, thereby
representing a potential mechanism underlying these ef-
fects. Studies have confirmed that, compared with the
treatment of unsynchronized ovarian cancer cells, PTX
treatment induces a higher rate of apoptosis in cells syn-
chronized to the G2/M phase [25]. It can also be specu-
lated that pretreatment of cells with SAHA for 24 h
effectively induced cell apoptosis and increased cell sen-
sitivity to subsequent drug treatment. In addition, SAHA
treatment alone causes a concentration-dependent in-
crease in autophagosomes in OC3/P cells (Figure 5A, B),
indicating that SAHA induces autophagy in OC3/P cells.
However, Chen. [18] reported that SAHA alone did not
induce autophagy in ovarian cancer cells. These incon-
sistencies may be due to the use of different SAHA con-
centrations and cell lines. In addition, our study showed
that PTX alone did not induce cell autophagy, but when
combined with SAHA, cell autophagy was significantly
enhanced compared with SAHA alone. These observa-
tions indicate that autophagy is involved in the mechan-
ism by which SAHA enhances the effects of PTX. In
view of this, the expression of genes and proteins related
to cell apoptosis was analyzed. The pro-apoptosis gene
bax and the anti-apoptosis gene bcl-2 play important
roles in Bcl-2 family protein-regulated cell apoptosis.
Our study showed that the SAHA in combination with
PTX significantly reduced the expression of bcl-2 genes
Figure 7 Effects of SAHA or/and PTX on the expression of intracellular genes and proteins in OC3/P cells. A–C: Quantitative RT-PCR
analysis of bcl-2, bax, c-myc and mdr1 gene expression in OC3/P cells treated with SAHA or/and PTX. *P <0.05 and **P <0.01 indicate significant
differences compared with the control group and drug along group. D: Western blot analysis of caspase-3 and Id1 protein expression in OC3/P
cells treated with SAHA or/and PTX. *P <0.05 indicate significant differences compared with the control group and drug along group.
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(Figure 7A); this observation is in accordance with those
reported by Charles [22].
The caspase family plays a very important role in apop-
tosis, with the cysteine aspartic acid protease caspase-3 as
a key molecule that transmits apoptotic signals in multiple
signaling pathways [26]. Our research showed that the
caspase-3 protein expression in cells increased after treat-
ment with PTX in combination with SAHA. C-myc can
stimulate unlimited cell proliferation, promote cell div-
ision, and is also involved in apoptosis. This molecule is
closely associated with the occurrence and development
of a wide variety of tumors [27,28]. Our study showed that
treatment of OC3/P cells with SAHA alone for 24 h sig-
nificantly reduced c-my-c gene expression (Figure 7B);
however, in combination with low dose PTX (2 μM), no
statistical difference was observed in the changes in c-myc
observed in response to SAHA treatment alone. In con-
trast, intracellular c-myc expression decreased compared
with SAHA alone (P <0.05) when combined with highPTX concentrations (up to 20 μM). These observations
indicate that mechanism underlying apoptosis induced by
SAHA alone or combined with PTX is also associated
with changes in c-myc expression.
It has been speculated that paclitaxel resistance is
mainly related to overexpression of the multi-resistance
gene, mdr1, tubulin mutations and bcl-2 expression disor-
ders [29-33]. Our study showed a significant decrease in
intracellular mdr1 gene expression in OC3/P cells treated
with SAHA alone for 24 h compared with that in the con-
trol group (Figure 7C). Furthermore, in this study, SAHA
reduced intracellular bcl-2 gene expression, which not
only represents a mechanism of apoptosis-induction, but
may also be involved in the reduction of drug resistance.
This indicates that SAHA has the potential to reverse pac-
litaxel resistance in ovarian cancer. In addition, mdr1 ex-
pression was upregulated in OC3/P treated with PTX
alone (2 μM for 24 h) (Figure 7C), indicating that low
doses of PTX, not only had no apoptotic effects, but also
enhanced the resistance of these cells. These results may
Liu et al. Cancer Cell International 2014, 14:112 Page 8 of 11
http://www.cancerci.com/content/14/1/112also account for the lack of significant effects on cell sur-
vival, migration and apoptosis observed in OC3/P treated
with PTX alone (2 μM for 24 h). Treatment with PTX
(2 μM) alone was associated significantly increased intra-
cellular nuclear abnormalities, which were indicative of
enhanced cell resistance. Taken together, these observa-
tions indicate that in the combined SAHA and PTX treat-
ment of paclitaxel-resistant ovarian cancer cells, SAHA
pretreatment provides an enhanced antitumor effect.
Inhibitors of differentiation or inhibitors of DNA-binding
(Id) proteins are widely expressed transcriptional factor
with four subtypes: Id1, Id2, Id3 and Id4. These proteins
exert negative regulatory effects on cell growth and tissue-
specific differentiation by inhibiting further differentiation
and maturation after cell division, affecting cell-cycle regu-
lation and promoting proliferation of vascular endothelial
cells to promote invasion and metastasis by malignant
tumor. Studies have shown that Id1 is highly expressed in
ovarian cancer, thus promoting proliferation and inhibit-
ing apoptosis and differentiation of ovarian cancer cells
[34,35]. Moreover, Maw found that the expression of Id1
was related positively to the clinical stage of ovarian
cancer patients, with higher expression associated with
more obvious tumor angiogenesis and poorer prognosis
[36]. It has been reported [37] that trichostatin (TSA)
effectively inhibits in vitro proliferation and induces
anti-differentiation of the sensitive ovarian cancer cell
line A2780 via a mechanism that involves downregula-
tion of Id1 protein expression. TSA and SAHA are both
HDACIs; therefore, it can be speculated that SAHA has
the potential to induce anti-differentiation of paclitaxel-
resistant ovarian cancer cells. This study showed that
SAHA alone or in combination with PTX effectively re-
duced the intracellular expression of Id1 protein. Light
and electron microscopy investigations also revealed
that SAHA (4 μM and 16 μM) treatment of OC3/P
wasassociated with changes in nuclear shape, mostly
round, cytoplasm increases, microvilli on the cell mem-
brane does not reduce or increase, hence indicating that
the induction of anti-differentiation represents another
mechanism by which SAHA exerts antitumor activity
and enhances the sensitivity of OC3/P cells to PTX.
However, treatment with a high concentration of SAHA
(64 μM) stimulated apoptosis and autophagy predomin-
antly, therefore, the optimal SAHA dose regimen required
to induce anti-differentiation in resistant ovarian cancer
cell lines requires further exploration.
In conclusion, SAHA inhibits growth of paclitaxel-
resistant ovarian cancer cells, diminishes migration
capacity, causes cell-cycle arrest, induces apoptosis and
autophagy. In addition, SAHA has the potential to reverse
ovarian cancer drug resistance and induce inverse differ-
entiation. These effects are enhanced by pretreatment
with SAHA in a combined SAHA and PTX regimen.Methods
Reagents and drugs
The HDACI suberoylanilide hydroxamic acid (SAHA,
vorinostat) was provided by Selleck Chemicals (Houston,
TX, USA). Paclitaxel was obtained from Bristol-Myers
Squibb (Princeton, NJ, USA). RPMI 1640 medium was
purchased from Gibco BRL (Grand Island, NY, USA).
Thymidine and DMSO were purchased from Sigma-
Aldrich (St. Louis, MO, USA). A cell apoptosis kit was
purchased from Beijing Baosai Technological Corporation
(Beijing, China).CCK-8 was purchased from KEYGEN
BIOTECH (Nanjing, China). Anti-cleaved caspase-3
was obtained from Cell Signaling Technology (Beverly,
MA, USA). Anti-ID1 was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
SAHA was dissolved in dimethyl sulfoxide (DMSO) and
stored at −70°C until used. SAHA and PTX were diluted
to appropriate concentrations in culture medium 1640
and the final concentration of DMSO was less than 0.1%
(vol/vol).Cell lines and cell culture
OC3 and the derived paclitaxel-resistant cell line, OC3/
P, were obtained from the Department of Obstetrics and
Gynecology of Beijing Shijitan Hospital of Capital Medical
University (China). The paclitaxel-resistant cell line,
OC3/P, was induced from OC3 cells by repeat exposure to
300 μg/mL paclitaxell for approximately 2 h each time
over a period of 10 months. The cells were cultivated as
monolayers in RPMI 1640 medium with 10% heat-
inactivated fetal calf serum (HI FCS; PAA Laboratories
Gmb) at 37°C in a 5% CO2 atmosphere. The culture
medium was replaced every 2 days.Cell morphology observations with light and electron
microscopy
For light microscopy, exponentially growing cells (OC3
and OC3/P) were transferred to 6-well plates and cultured
at 37°C in a 5% CO2 atmosphere. When the cells were
60% to 70% confluent, the cells were rinsed twice with
PBS and the supernatant was discarded. Then, cells were
fixed in 4% paraformaldehyde for 20 min and stained by
the Wright-Giemsa method.
Transmission electron microscopy (TEM) was used to
confirm the morphological features of the induction of
apoptosis and autophagy of OC3/P treated with SAHA
or PTX alone or in combination by examination of the
alterations in the subcellular structures. Cultured cells
were fixed and prepared for TEM as described previously
[38]. Representative areas were chosen for ultrathin
sectioning and photographs were taken with the H-7650
transmission electron microscope (Hitachi Limited,
Tokyo, Japan).
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OC3 and OC3/P cells in the exponential phase were
digested separately using 0.25% trypsin and harvested.
Single-cell suspensions were prepared. OC3 and OC3/P
cells were counted separately using a hemocytometer,
added to 96-well microtiter plates (5 × 103 cells/well) and
cultured at 37°C under 5% CO2. Each cell line was tested
in triplicate CCK-8 assays every 24 h for 6 days. Two
hours before measuring the absorbance, 10 μl of the CCK-
8 solution was added into each well. Absorbance at
450 nm was measured using the ELX800 microplate
reader (BIO-TEK, USA). Three control wells without
cells were prepared and the average absorbance of the
control wells was subtracted from that of the corre-
sponding sample wells; doubling-time was calculated
according to a previously described method [25]. Each
experiment was performed in triplicate.
OC3 and OC3/P cells were added separately to 96-well
plates (1.2 × 104 cells/well) and cultured at 37°C under
5% CO2 for approximately 24 h prior to the addition of
drugs. PTX (0.02, 0.2, 2, 20 and 200 μM) was added to
OC3 and OC3/P cells and viability was evaluated after
24 h and 48 h using CCK-8 assays as described pre-
viously. Resistance index (RI) was equal to the ratio of
the inhibitory concentration 50% (IC50) values of resist-
ant to sensitive cells. Each experiment was performed in
triplicate.
Cell viability
OC3 and OC3/P cells were incubated in 96-well plates
(1.2 × 104 cells/well) for 24 h prior to treatment with
various concentrations of SAHA for 48 h and various
concentrations of PTX for 24 h. Cell viability was deter-
mined using CCK-8 assay.
OC3/P cells (1.2 × 104 cells/well) were plated in tripli-
cate in 96-well plates for 24 h and treated with various
drug groups (Control group: serum-free 1640 for 48 h;
SAHA group: SAHA 1640 dilution for 24 h followed by
serum-free 1640 for 24 h; PTX group: serum-free 1640 for
24 h followed by PTX 1640 dilution for 24 h; SAHA +
PTX group: SAHA 1640 dilution for 24 h followed by
PTX 1640 dilution for 24 h). The cell viability of each
group was determined by CCK-8 as described previously.
Wound healing assay
Wound healing assays were conducted as a measure of
cell migration and invasion capacity. OC3/P cells in the
exponential growth phase were trypsinized and plated
into 6-well plates (4 × 104 cells/well). After incubation at
37°C under 5% CO2 for 24 h, cells were treated with
PTX or SAHA alone or in combination (the co treat-
ment is same with the way in cell viability of methods).
A wound was made by scraping the cell monolayers with
a 200 μl micropipette tip. Photographs were takenimmediately and after 12 h, 24 h and 36 h using an
IX70 microscope (OLYMPUS, Japan).
Flow cytometric analysis of cell-cycle apoptosis
At approximately 40% confluence, 8 mM thymidine was
added to OC3/P cells cultured in 6-well plates. After
15 h, the cells were rinsed twice with PBS and the culture
medium was replaced with fresh medium (RPMI 1640
medium with 10% HI FCS). After a further 11 h, the cells
were treated with thymidine for an additional 15 h. Then,
the cells were treated with SAHA or PTX alone or in
combination and harvested at the indicated time. The cells
were washed with PBS, fixed in 70% ethanol, and stored at
4°C overnight. The fixed cells were washed twice in PBS
and the supernatant was discarded. After resuspension in
100 μl PBS containing RNase A (1 mg/ml, Sigma), cells
were incubated for 30 min at 37°C. The samples were
stained with 400 μl propidium iodide (PI) and then de-
tected using a Cytomics FC500 flow cytometer (Beckman
Coulter, Brea, CA, USA). Cell-cycle distribution was cal-
culated using CXP Software (Beckman Coulter), with the
number of gated cells in G1, S and G2 phase presented
as a percentage. Each experiment was performed in
triplicate.
After incubation with SAHA or PTX alone or in com-
bination, OC3/P cells were harvested at the indicated
times. The cells (at least 1.0 × 106 events) were rinsed
twice with PBS and the supernatant was discarded. The
cells were then resuspended in 200 μl of buffer. Annexin
V-FITC (10 μl) was added to the cell suspension, mixed
slightly and maintained at room temperature for 15 min
or at 4°C for 30 min (in darkness). Subsequently, buffer
(300 μl) and PI (5 μl) were added to determine that the
apoptotic rate using a Cytomics FC500 flow cytometer
(Beckman Coulter) over a 1 h period. The percentage
of apoptotic cells in each quadrant was calculated
using CXP Software. Each experiment was performed
in triplicate.
Quantitative real-time polymerase chain reaction (quanti-
tative RT-PCR)
Total RNA isolation and cDNA synthesis from OC3/P
cells treated with SAHA or PTX alone or in combination
were performed using Trizol and the Takara Reverse Tran-
scriptase kit (Takara, Otsu, Japan), respectively, according
to the manufacturer’s instructions. The cDNA encoding
the indicated genes was amplified with the following spe-
cific primers:




and 5’-CCGAAGGAGAAGGGTGT-3’; mdr1, 5’-ATAAT
GCGACAGGAGATAGGC-3’ and 5’-ATGTTGCCATT
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TGAA-3 and 5-CTAAGTCATAGTCCGCCTAGAAGC
A-3. Real-time PCR was performed using the UltraSYBR
Mix (CWBIO, Beijing, China) with the Mx3000p Real-
Time PCR System (Stratagene, La Jolla, CA, USA) using
the following thermal cycling conditions: 10 min at 95°C
followed by 40 cycles of 10 s at 95°C, 30 s at 60°C, and
30 s at 72°C. Data were analyzed according to the 2 –ΔΔCt
method.
Western blot analysis
After OC3/P cells were treated with SAHA or PTX
alone or in combination, they were harvested and lysed.
Then total protein concentrations of cell lysates were de-
termined by the BCA Protein Assay kit (Thermo Fisher
Scientific, Waltham, MA, USA). Protein samples (60 μg)
were separated by 12% SDS-PAGE and transferred onto
a PVDF membrane. The membranes were incubated for
1 h in TBST buffer containing 5% skimmed dried milk
to block non-specific binding before incubation with the
diluted primary antibody overnight at 4°C with gentle
shaking. Subsequently, membranes were incubated with
the secondary antibody for 1 h at room temperature.
The membrane was washed three times in TBST, for
5 min each time, then treated with mixture of chemilu-
minescence substrate liquid A and liquid B (1:1 ratio)
for 5 min in darkness.
Statistical analysis
The experimental data are shown as the mean ± SD.
SPSS18.0 software (Chicago, USA) was used to perform
statistical analysis. Statistical comparisons were made
using ANOVA, or t-test. A P value <0.05 was consid-
ered to indicate statistical significance.
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